A study found that teens with obesity eat more later in the day than their peers, highlighting the role of the body’s circadian system in eating habits. A new study from researchers at Mass General ...

Panelists discuss the prevalence of treatment-refractory moderate to severe atopic dermatitis, noting factors such as intolerance or inability to use high-potency topical agents as common reasons for ...

Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) ...

Panelists discuss treatment expectations for newer systemic agents, highlighting data on efficacy onset and persistence, including rapid improvement in pruritus with dupilumab by week 2 (SOLO trials), ...

His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit.

Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN offers her thoughts on the recent FDA approval of GSK's meningococcal ABCWY vaccine. On February 14, 2025, the FDA approved ...

The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally. The FDA has approved ...

Video content above is prompted by the following: 4. How do the treatment options evolve as a child ages? a. FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, ...

The federal agency has approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.

His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit. An 8-year-old boy presented to the pediatrician’s office for ...

LIB Therapeutics has announced that the FDA has accepted its biologics license application (BLA) for lerodalcibep, a treatment designed to lower low-density lipoprotein cholesterol (LDL-C) in patients ...

The new risdiplam tablet is suitable for those aged 2 years and older who weigh more than 44 lbs, according to Genentech. Genentech has received FDA approval for the risdiplam (Evrysdi) tablet new ...